German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline
Thursday, Germany's competition authority, Bundeskartellamt, cleared the planned acquisition of Cardior Pharmaceuticals GmbH by Danish pharma giant Novo Nordisk A/S (NYSE:NVO).
週四，德國競爭管理機構Bundeskartellamt批准了丹麥製藥巨頭諾和諾德A/S（紐約證券交易所代碼：NVO）收購Cardior Pharmicals GmbH的計劃。
Cardior is a biotech company focusing on heart diseases, in the case at hand cardiac insufficiency or heart failure.
Cardior是一家生物技術公司，專注於心髒病，例如心臟功能不全或心力衰竭。
The company has not yet offered any approved substances. Cardior's main development product is an active substance against cardiac insufficiency caused by heart attacks.
該公司尚未提供任何經批准的物質。Cardior的主要開發產品是一種針對心臟病發作引起的心功能不全的活性物質。
In March, Novo Nordisk agreed to acquire Cardior for up to €1.025 billion. The agreement includes Cardior's lead compound, CDR132L, which is currently in phase 2 clinical development for the treatment of heart failure.
3月，諾和諾德同意以高達10.25億歐元的價格收購Cardior。該協議包括Cardior的主要化合物 CDR132L，該化合物目前處於治療心力衰竭的第二階段臨床開發階段。
The acquisition is an important step forward in Novo Nordisk's strategy to establish a presence in cardiovascular disease.
此次收購是諾和諾德在心血管疾病領域建立業務的戰略向前邁出的重要一步。
"By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programs across all phases of clinical development," said Martin Holst Lange, executive vice president for Development at Novo Nordisk.
諾和諾德開發執行副總裁馬丁·霍爾斯特·蘭格表示：“通過歡迎Cardior加入諾和諾德，我們將加強我們在心血管疾病領域的項目渠道，我們已經在臨床開發的各個階段進行了持續的項目。”
CDR132L is designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132. This could potentially lead to long-lasting improvement in heart function.
CDR132L 旨在通過選擇性地阻斷 microRNA 分子 miR-132 的異常水平來阻止和部分逆轉細胞病理。這有可能導致心臟功能的長期改善。
In a phase 1b trial published in the European Heart Journal, CDR132L was reported to be safe and well tolerated. The results suggested cardiac functional improvements in people with heart failure compared to placebo.
在《歐洲心臟雜誌》上發表的一項1b期試驗中，據報道，CDR132L 安全且耐受性良好。結果表明，與安慰劑相比，心力衰竭患者的心臟功能有所改善。
CDR132L is currently being investigated in the phase 2 trial HF-REVERT in 280 people with heart failure with reduced ejection fraction (HFrEF) who have previously suffered a heart attack (myocardial infarction). The first patient was dosed in the HF-REVERT trial in July 2022.
HF-REVERT 的 2 期試驗目前正在研究 CDR132L，該試驗針對 280 名先前曾遭受過心臟病發作（心肌梗塞）的心力衰竭、射血分數降低的心力衰竭（HFref）患者。2022年7月，在HF-REVERT試驗中，第一位患者接受了給藥。
Novo Nordisk plans to initiate a second phase 2 trial that will investigate CDR132L in a chronic heart failure population with cardiac hypertrophy – a condition characterized by thick and stiff heart muscles.
Novo Nordisk計劃啓動第二階段試驗，該試驗將調查伴有心臟肥大的慢性心力衰竭人群中的 CDR132L，這種疾病的特徵是心肌粗壯而僵硬。
The deal is expected to close in the second quarter of 2024.
該交易預計將於2024年第二季度完成。
Price Action: NVO shares are down 1.42% at $122.77 at the last check Thursday.
價格走勢：在週四的最後一次檢查中，NVO股價下跌1.42％，至122.77美元。
Photo via Shutterstock
照片來自 Shutterstock